SynthesisFrontiers in oncology2026
Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis.
Xiao Ma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.